ASCO: Merck's Keytruda trips in EGFR lung cancer as Roche's Tecentriq fails in kidney cancer

The PD-1/L1 inhibitor class of drugs has vastly improved care for many patients with cancer, but some meds in the class have posted trial failures lately. At the American Society of Clinical Oncology's recent annual meeting, two trial failures for class leaders were on display.